• Explore /
  • Poster
  • / Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).

Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).

Abstract Video & Slides Poster

Authors

null

Ruemu Ejedafeta Birhiray

Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN

Ruemu Ejedafeta Birhiray , Stefano Luminari , Tae Min Kim , Münci Yağcı , Timothy Robert Wassenaar , Ashish Risal , Manjusha Namuduri , Jingxian Cai , Bertha Fearon-Chalet , Min Zhu , Sushmita Mukherjee , Jurriaan Brouwer-Visser , Aafia Chaudhry , Hesham Mohamed , Srikanth R Ambati , Umberto Vitolo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT06091254

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS7096)

DOI

10.1200/JCO.2024.42.16_suppl.TPS7096

Abstract #

TPS7096

Poster Bd #

72b

Abstract Disclosures

Similar Posters

First Author: Umberto Vitolo

First Author: John M. Pagel

First Author: Colin Hardin

First Author: Timothy M Illidge